超星 - test 5 - 查题吧

单选题

The medical geneticist Clyde E. Keeler (1900-1994) in _______ was probably the first to use the term 'gene therapy', although the process he was describing (the correction of gene-based deviations in plants and animals) was not envisaged as an effective therapeutic technique to treat genetic diseases in man.

A. 1940
B. 1947
C. 1952
D. 1957

单选题

The first deliberate transfer of foreign genes into human recipients with a therapeutic purpose, was performed in ______ by the American physician Stanfield Rogers who attempted to treat three German siblings presenting with arginase deficiency, by giving them injections of the native Shope rabbit papilloma virus, but he failed.

A. 1960
B. 1965
C. 1970
D. 1978

单选题

The first recombinant DNA molecule was produced in ______ by Stanford researcher Paul Berg (1926- ). Berg joined together DNA fragments from two different viruses with the help of restriction enzymes and ligase.

A. 1968
B. 1972
C. 1975
D. 1978

单选题

In ______, Theodore Friedmann and Richard Roblin published an important paper in Science [175(4025): 949-955] describing the use of gene therapy. Friedmann and Roblin described how they induced mammalian cells to express bacterial and viral DNA, demonstrating the possibility that this method could later be used to promote therapies for treatment of human genetic diseases.

A. 1965
B. 1969
C. 1972
D. 1975

单选题

In 1973 Herbert Wayne Boyer at UCSF (1936- ) and Stanley Norman Cohen at Stanford University (1935- ) created the first recombinant DNA organisms. Together they introduced an antibiotic resistance gene into _______.

A. elegans
B. yeast
C. coli
D. mice

单选题

In 1983, a group of scientists from Baylor College of Medicine in Houston, Texas, proposed that gene therapy could one day be a viable approach for treating Lesch-Nyhan disease, a rare ___________________.

A. blood disorder
B. neurological disorder
C. bone disorder
D. joint disorder

单选题

In ______, Glybera (alipogene tiparvovec) became the first approved viral gene-therapy treatment for familial lipoprotein lipase deficiency (LPLD) in Europe.

A. 2006
B. 2010
C. 2012
D. 2015

单选题

The marketing authorization for Glybera clearly represents a milestone in the development of gene therapy as an accessible therapeutic option for familial lipoprotein lipase deficiency (LPLD) patients. Glybera is a recombinant __________ for direct intramuscular injection.

A. adenovirus
B. AAV
C. HPV
D. retrovirus

单选题

In March 2017, Yescarta (axicabtagene ciloleucel), a ________-directed genetically modified autologous T cell immunotherapy, was approved by FDA.

A. CD15
B. CD19
CD29
D. CD44

单选题

On August 30, 2017, the US FDA approved Kymriah (tisagenlecleucel, Novartis)for the treatment of patients aged ≤25 years with B-cell precursor ______________________ that is refractory, in second relapse, or later relapse.

A. acute myelogenous (or myeloid) leukemia (AML)
B. acute lymphocytic (or lymphoblastic) leukemia (ALL)
C. chronic myelogenous (or myeloid) leukemia (CML)
D. chronic lymphocytic (or lymphoblastic) leukemia (CLL)

14